We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies. Cookie Policy

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

ADVERTISEMENT
Africanian
  • News
  • News 24/7
  • Politics
  • Business
  • Health
  • Sports
  • Travel
  • World
    • US
    • Russia
    • Europe
    • Asia
    • America
  • Events
No Result
View All Result
Africanian
No Result
View All Result
Home World

WHO resumes hydroxycholorquine trial after ‘threat’ queried

"On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol," Tedros told a virtual news conference from Geneva.

in World
Reading Time: 2 mins read
0 0
0
WHO resumes hydroxycholorquine trial after 'threat' queried
0
SHARES
Share on FacebookShare on TwitterShare via Whatsapp

The World Health Organization, or WHO, said on Wednesday that it will resume trials of anti-malaria drug hydroxycholorquine as a potential treatment of COVID-19 after having previously announced a temporary pause early last week.

WHO Director-General Tedros Adhanom Ghebreyesus said the executive group of the Solidarity Trial program had decided to implement a temporary pause last week because of concerns raised about the safety of the drug. The decision was taken as a precaution while the safety data was reviewed, something that has since been done by the Trial’s Data Safety and Monitoring Committee.

“The executive group received this recommendation and endorsed continuation of all arms of the Solidarity Trial, including hydroxychloroquine.”

He said the executive group will communicate with the principal investigators in the trial about resuming the hydroxychloroquine arm of the trial.

The WHO’s announcement of a temporary halt, made on May 25, came after a paper published in medical journal The Lancet showed that people taking hydroxychloroquine were at higher risk of death and heart problems than those who were not.

More

India leads a technical response following the Boeing 787 crash

China implements visa exemption for Saudi Arabia, Oman, Kuwait, and Bahrain

Is the United States of America Still the Land of Opportunity?

The drug has been in the spotlight after United States President Donald Trump publicly promoted it at various occasions. Weeks ago, Trump claimed he was taking it as a precaution, but he said last week that he had finished taking it.

The Lancet articles have now turned out to be problematic. A report on ScienceMag.org on Tuesday said that the Lancet results have begun to unravel, and Surgisphere, which provided patient data for two other high-profile COVID-19 papers, has come under withering online scrutiny from researchers and amateur investigators.

They have pointed out many red flags in the Lancet paper, including the number of patients involved and details about their demographics and prescribed dosing that seem implausible.

“It began to stretch and stretch and stretch credulity,” Nicholas White, a malaria researcher at Mahidol University in Bangkok, was quoted as saying.

On Wednesday, Soumya Swaminathan, the WHO’s chief scientist, said she hopes the ongoing trial will continue until it has definite answers whether it works or not.

“That can only be done through well conducted randomized trials,” she said.

Source: China Daily
Africanian

Africanian

  • Trending
  • Comments
  • Latest
Rwanda combines youth innovation and circular economy to build a resilient nation

Rwanda combines youth innovation and circular economy to build a resilient nation

July 3, 2025
Weather in South Africa: Climate and Seasons

Weather in South Africa: Climate and Seasons

August 25, 2020
7 Tracks, 1 Future: AfriLabs Annual Gathering 2025 Sets the Stage for Africa’s Innovation Renaissance

7 Tracks, 1 Future: AfriLabs Annual Gathering 2025 Sets the Stage for Africa’s Innovation Renaissance

June 25, 2025
In Tanzania, the Kibuka community has improved their household economy by more than 50%.

In Tanzania, the Kibuka community has improved their household economy by more than 50%.

July 11, 2025
Lesotho increases blood collection by 70% between 2017 and 2024

Lesotho increases blood collection by 70% between 2017 and 2024

July 8, 2025
Nigeria accelerates economic transformation with key reforms and signs of recovery

Nigeria accelerates economic transformation with key reforms and signs of recovery

July 7, 2025
Twitter Instagram Youtube Facebook
No Result
View All Result

Africanian News

Is a dedicated project aimed at amplifying the voices of the African Ecosystem and Diaspora. We actively collaborate with initiatives to improve access to education and digital inclusion, both in traditional schools and through digital platforms, for African children.

It’s crucial to emphasize that none of the articles or images featured on our platform are intended for copyright infringement, neither now nor in the future. If you believe that any information, text, image, etc., may be subject to copyright and should be removed, please notify us by sending an email to info@africanian.com

Your dreams matter; your stories matter.

Feel free to explore collaboration opportunities with us. Share your articles, thoughts, interviews, experiments, or no-comment videos by reaching out to info@africanian.com. You can also subscribe to our mailing list to receive the latest updates from Africanian News.

© 2024 Africanian News: From Africa, by Africans, for Africa, and friends of Africa.

No Result
View All Result
  • News
  • Politics
  • Business
  • Health
  • Sports
  • Entertainment
  • Tech
  • Travel
  • World

© 2024 Africanian News: From Africa, by Africans, for Africa, and friends of Africa.

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Log In

Sign In

Forgot password?

Don't have an account? Register

Forgot password?

Enter your account data and we will send you a link to reset your password.

Back to Login

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Accept

Add to Collection

  • Public collection title

  • Private collection title

No Collections

Here you'll find all collections you've created before.